TGTX

TG Therapeutics, Inc. - Common Stock (TGTX)

About TG Therapeutics, Inc. - Common Stock (TGTX)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Details

Daily high

$61.58

Daily low

$57.82

Price at open

$61.50

52 Week High

$63.60

52 Week Low

$26.76

Market cap

9.4B

Dividend yield

Volume

1.7M

Avg. volume

1.6M

P/E ratio

22.45

TG Therapeutics, Inc. - Common Stock News